N@N

ACGY, BRKR, ALGN, SPPI, SBH, DSCO. Abnormal Price Friction In Morning Trading Session Today

^{Published on 2009-06-16 08:09:15, Last Modified on 2010-12-22 14:13:46 - WOPRAI}
 

June 16, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 16, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This fair market making requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the companies with Abnormal Price Friction (unfair market) in their stock prices in today�s trading session. This means that there was more buying than selling in the stocks and their stock prices dropped. Acergy (NASDAQ: ACGY), Bruker Corp (NASDAQ: BRKR), Align Technology (NASDAQ: ALGN), Spectrum Pharmaceuticals (NASDAQ: SPPI), Sally Beauty Holdings (NYSE: SBH) and Discovery Laboratories (NASDAQ: DSCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

ACGY -$0.46 -4.29% 73,301 59.51% 49,867 40.49% 23,434 abnormal

BRKR -$0.43 -5.11% 82,573 66.69% 41,044 33.15% 41,529 abnormal

ALGN -$0.35 -3.35% 58,939 49.72% 58,409 49.27% 530 abnormal

SPPI -$0.29 -4.72% 240,915 50.56% 235,381 49.40% 5,534 abnormal

SBH -$0.22 -3.50% 44,709 38.36% 39,893 34.23% 4,816 abnormal

DSCO -$0.13 -10.24% 851,502 50.05% 842,561 49.53% 8,941 abnormal

Click here to view chart:

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above had more buying than selling on Tuesday, June 16th, 2009 and their stock prices dropped. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ACGY with 23,434 greater shares of buying than selling (NetVol) and the stock price was down -$0.46. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more buying than selling should cause prices to rise.

Acergy S.A. (NASDAQ: ACGY) is a seabed-to-surface engineering and construction contractor to the offshore oil and gas industry worldwide. We provide integrated services, and we plan, design and deliver complex projects in harsh and challenging environments.

Bruker Corporation (NASDAQ: BRKR) designs and manufactures life science and materials research systems and associated products worldwide. Its BioScience segment offers advanced instrumentation and automated solutions based on X-ray technology, OES-spark technology, mass spectrometry technology, and infrared and Raman molecular spectroscopy technologies. It offers x-ray systems, computer-controlled positioning systems, sample handling devices, and data collection and analysis software to acquire, analyze, and manage elemental and molecular information. This segment also provides mass spectrometers that measure the mass or weight of molecules, as well as offers mass spectrometry systems and integrated solutions for applications in life-science markets, including genomics, expression proteomics, clinical proteomics, metabolic and peptide biomarker profiling, drug discovery and development, molecular diagnostics research, molecular and systems biology, and basic molecular medicine research. In addition, it offers instruments for life science, pharmaceutical analysis, and food and agricultural analysis in research and development, quality control, and process analysis applications. The company�s BioSpin offers life science analysis instruments based on magnetic resonance, a natural phenomenon occurring when a molecule gives off a signature radio frequency. It develops superconducting wire materials used in various applications, including power cables, motors, generators, and superconducting magnets. Bruker Corporation serves pharmaceutical, biotechnology, proteomics and molecular diagnostic, semiconductor, chemical, cement, metals and petroleum, food, beverage, and agricultural companies, as well as academic institutions, government agencies, and raw material manufacturers. The company was formerly known as Bruker BioSciences Corporation and changed its name to Bruker Corporation in February 2008. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

Align Technology, Inc. (NASDAQ: ALGN) designs, manufactures, and markets the invisalign system for treating malocclusion or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. The company�s products include Invisalign Full for the treatment of a range of malocclusions; Invisalign Express, a solution for less complex orthodontic cases; Invisalign Teen, which is designed to meet the specific needs of the non-adult comprehensive or teen treatment market; Vivera retainers that offer aesthetic retention solution for invisalign and non-invisalign patients; and Invisalign Assist, which is designed for general practitioners for selecting, monitoring, and finishing invisalign cases. It also offers ancillary products comprising cleaning material and adjusting tools for dental professionals. Align Technology, Inc. distributes its products directly to orthodontists and general practitioner dentists in North America, Europe, the Asia Pacific, Latin America, and Japan. The company was founded in 1997 and is headquartered in Santa Clara, California.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a commercial-stage biotechnology company with a focus on oncology, develops and commercializes a portfolio of drug products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma (NHL); and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company is also developing apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products include Ozarelix, a drug being investigated for benign prostatic hypertrophy (BPH), a non-cancerous enlargement of the prostate, and hormone dependent prostate cancer; and Ortataxel, a third-generation taxane. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Sally Beauty Holdings, Inc. (NYSE: SBH) engages in the distribution and retail of professional beauty supplies. It operates in two segments, Sally Beauty Supply and Beauty Systems Group. The Sally Beauty Supply segment offers third-party branded and label beauty products, including hair care products, styling appliances, skin and nail care products, and other beauty items to retail consumers and salon professionals. It offers beauty products from the Clairol, Revlon and Conair brand names. The Beauty Systems Group segment operates as a beauty supply distributor offering professional brands directly to salons and salon professionals through its sales force and professional-only stores. As of September 30, 2008, Sally Beauty Holdings operated 3,580 stores and supplied to 193 franchised stores in North America, as well as in selected European countries and Japan. The company was founded in 1964 and is headquartered in Denton, Texas.

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company�s proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,600,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net